(Q40889718)

English

Oral idarubicin. A review of its pharmacological properties and clinical efficacy in the treatment of haematological malignancies and advanced breast cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

1 reference

Europe PubMed Central

Oral idarubicin. A review of its pharmacological properties and clinical efficacy in the treatment of haematological malignancies and advanced breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

author name string

Buckley MM

1

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Lamb HM

2

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

publication date

1 July 1997

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

61-86

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

https://scigraph.springernature.com/pub.10.2165/00002512-199711010-00006

0 references

Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma pharmacokinetics of Idarubicin and its 13-hydroxymetabolite after intravenous and oral administration under fasting and non-fasting conditions

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The treatment of acute leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of idarubicin (4-demethoxydaunorubicin) in advanced breast cancer. The Clinical Screening Group of the European Organization for Research and Treatment of Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravenous and oral demethoxydaunorubicin (NSC 256-439) in the treatment of acute leukemia and lymphoma: a pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

P170 glycoprotein expression and impaired anthracycline retention in chronic myeloid leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Weekly oral 4-demethoxydaunorubicin in patients with relapsed low grade non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The new anthracycline 4-demethoxydaunorubicin by oral route in advanced pretreated breast cancer and melanoma. A pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationship between effects on nucleic acid synthesis in cell cultures and cytotoxicity of 4-demethoxy derivatives of daunorubicin and adriamycin

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral idarubicin in elderly patients with acute myeloid leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral idarubicin plus cytosine arabinoside in the treatment of acute non lymphoblastic leukemia in elderly patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of drug resistance is reduced with idarubicin relative to other anthracyclines

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination chemotherapy with 5-fluorouracil, oral Idarubicin, and cyclophosphamide (FIC) in metastatic breast cancer--an open phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of myelodysplastic syndromes with daily oral idarubicin. A phase I-II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Acute myeloid leukemia with poor prognosis: treatment with oral 4-demethoxydaunorubicin (idarubicin) and low-dose cytarabine via subcutaneous route]

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Idarubicin: an evaluation of cardiac toxicity in 77 patients with solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and metabolism of anthracyclines

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination of idarubicin and cyclophosphamide administered orally in untreated postmenopausal breast cancer patients. A phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group GIMEMA.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of oral idarubicin in elderly patients with advanced breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Weekly oral idarubicin in postmenopausal women with advanced breast cancer. A phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. A pharmacokinetic study

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Idarubicin in advanced breast cancer: a phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral administration of idarubicin as first line cytostatic therapy in patients with metastasized breast cancer and favourable prognosis. A trial of the phase II study group of the Association for Medical Oncology of the German Cancer Society

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivatives.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New anthracycline analogs in advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral idarubicin as a palliative agent in leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunomycin

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Idarubicin: an anthracycline antineoplastic agent

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical pharmacokinetics of idarubicin

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Idarubicin: a second-generation anthracycline

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

VAD chemotherapy as remission induction for multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potential role of oral anthracyclines in older patients with cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukaemia in the elderly: a report of toxicity and efficacy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Schedule-dependent efficacy of idarubicin (Ida) and doxorubicin (Dox).

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase-II trial of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral idarubicin and prednisone for advanced, previously untreated, multiple myeloma: a pilot study. Cooperative Group of Study and Treatment of Multiple Myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Good tolerance of weekly oral idarubicin: (4-demethoxydaunorubicin): a phase I study with pharmacology

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bioavailability and pharmacology of oral idarubicin

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral idarubicin as treatment for advanced myelodysplastic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of idarubicin and prednisone in multiple myeloma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic study of intravenous and oral idarubicin in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral idarubicin as single-agent treatment of acute nonlymphocytic leukemia in poor-risk patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral idarubicin in non-Hodgkin's lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

4-Demethoxydaunorubicin administered orally in advanced breast cancer. A phase II study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their beta anomers

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of acute myeloid leukemia in elderly patients with oral idarubicin as a single agent

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Base mutation analysis of topoisomerase II-idarubicin-DNA ternary complex formation. Evidence for enzyme subunit cooperativity in DNA cleavage

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination chemotherapy with oral idarubicin and cyclophosphamide for metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful oral chemotherapy with idarubicin in refractory anaemia with excess blasts

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral chemotherapy with idarubicin plus cyclophosphamide in advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral idarubicin and low dose cytarabine as the initial treatment of acute myeloid leukemia in elderly patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-performance liquid chromatographic analysis of idarubicin and fluorescent metabolites in biological fluids

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of new anthracycline analogs with the human tumor stem cell assay

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial with oral idarubicin in advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selected pharmacologic characteristics of idarubicin and idarubicinol

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of idarubicin given orally in the treatment of anthracycline-naive advanced breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor activity of new anthracycline analogues in combination with interferon alfa

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Idarubicin in blastic crisis of chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective randomized trial of doxorubicinversus idarubicin in the treatment of advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral Idarubicin in Elderly Acute Leukemia and Myelodyplastic Syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of cardiac toxicity of idarubicin (4-demethoxydaunorubicin).

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

DNA fragmentation as a consequence of cell cycle traverse in doxorubicin- and idarubicin-treated human lymphoma cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of oral idarubicin (4-demethoxidaunorubicin) in previously untreated elderly patients with non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The MDR phenotype in hematologic malignancies: prognostic relevance and future perspectives

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative phase II study of idarubicin versus doxorubicin in advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I/II trial of Z-Dex (oral idarubicin and dexamethasone), an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral idarubicin in elderly acute leukemia and refractory anemia with excess of blasts.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination of oral idarubicin and prednimustine in advanced breast cancer: a phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral idarubicin--an anthracycline derivative with unique properties

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antitumor activity of 4-demethoxydaunorubicin administered orally

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II evaluation of orally administered idarubicin in patients with advanced breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of oral idarubicin in favorable histology non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro circumvention of anthracycline--resistance in Ehrlich ascites tumour by anthracycline analogues.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytotoxicity of anthracyclines: correlation with cellular uptake, intracellular distribution and DNA binding

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of oral weekly 4-demethoxydaunorubicin in advanced breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic leukemias

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Flow cytometric study of idarubicin and daunorubicin accumulation and the effect of verapamil in leukemic cell lines and fresh cells from patients with acute non-lymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II trial of oral idarubicin plus dibromodulcitol in advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cellular pharmacology of idarubicinol in multidrug-resistant LoVo cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Idarubicin, intermediate-dose cytarabine, etoposide, and granulocyte-colony-stimulating factor are able to recruit CD34+/HLA-DR- cells during early hematopoietic recovery in accelerated and chronic phases of chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

D-verapamil downmodulates P170-associated resistance to doxorubicin, daunorubicin and idarubicin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Review: breast cancer in elderly patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/9237041

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00002512-199711010-00006

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40889718&oldid=1909610204"